2,3\',4,5\',6-pentahydroxybenzophenone 4-O-(6\'\'-benzoyl)-beta-D-glucopyranoside



Compound IDCDAMM00676
Common name2,3\',4,5\',6-pentahydroxybenzophenone 4-O-(6\'\'-benzoyl)-beta-D-glucopyranoside
IUPAC name[6-[4-(3,5-dihydroxybenzoyl)-3,5-dihydroxyphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl benzoate
Molecular formulaC26H24O12

Experimental data

Retention time6.51
Adduct[M+2H]2+
Actual mz265.069
Theoretical mz265.071
Error5.95
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.3118

Identifiers and class information

Inchi keyKMLCBJWFZDXLFN-BFEIJTHESA-N
SmilesO=C(OCC1OC(OC2=CC(O)=C(C(=O)C=3C=C(O)C=C(O)C3)C(O)=C2)C(O)C(O)C1O)C=4C=CC=CC4
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)3
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)14
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)528.468
Computed dipole moment(dipole)8.053
Total solvent accessible surface area (SASA)761.188
Hydrophobic component of SASA (FOSA)107.097
Hydrophilic component of SASA (FISA)371.026
Pie component of the SASA (PISA)283.065
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1437.09
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)12.55
Free energy of solvation of dipole (dip^2/V)0.0451281
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0368669
Globularity descriptor (glob)0.809089
Predicted polarizability in cubic angstroms (QPpolrz)45.072
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.314
Predicted octanol/gas partition coefficient (QPlogPoct)30.586
Predicted water/gas partition coefficient (QPlogPw)22.596
Predicted octanol/water partition coefficient (QPlogPo/w)0.458
Predicted aqueous solubility (QPlogS)-3.469
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.862
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.971
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)3.002
Predicted brain/blood partition coefficient (QPlogBB)-4.059
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.929
Predicted skin permeability, log Kp (QPlogKp)-6.016
PM3 calculated ionization potential (IP(ev))9.125
PM3 calculated electron affinity (EA(eV))0.423
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-0.487
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)220.89
Number of nitrogen and oxygen atoms (#NandO)12
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P13866SLC5A1Sodium/glucose cotransporter 1T54771SwissTargetPrediction
P34913EPHX2Epoxide hydrataseT35734SwissTargetPrediction
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction
P18405SRD5A1Steroid 5-alpha-reductase 1T70309SwissTargetPrediction
P18031PTPN1Protein-tyrosine phosphatase 1BT16347SwissTargetPrediction
P17706PTPN2T-cell protein-tyrosine phosphataseT49156SwissTargetPrediction
Q14534SQLESqualene monooxygenase (by homology)T93344SwissTargetPrediction
P05121SERPINE1Plasminogen activator inhibitor-1T15556SwissTargetPrediction and SEA
P24723PRKCHProtein kinase C etaT40149SEA
P05771PRKCBProtein kinase C betaT40276SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
Q9Y251HPSEHeparanaseT47623SEA
Q99808SLC29A1Equilibrative nucleoside transporter 1T13491SwissTargetPrediction
P52789HK2Hexokinase type IIT96685SEA
Q9NY91SLC5A4Low affinity sodium-glucose cotransporterT22583SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P35346SSTR5Somatostatin receptor 5T64830SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SwissTargetPrediction and SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SwissTargetPrediction and SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
Q15077P2RY6Pyrimidinergic receptor P2Y6T90782SEA
Q05513PRKCZProtein kinase C (PKC)T59190SwissTargetPrediction
P05129PRKCGProtein kinase C gammaT47107SEA
P04637TP53Tumour suppressor p53/oncoprotein Mdm2T15739SwissTargetPrediction
P09382LGALS1Galectin-1T09544SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T54771DI0120Diabetes mellitus[ICD-11: 5A10]P13866SLC5A1
T54771DI0175Heart failure[ICD-11: BD10-BD1Z]P13866SLC5A1
T54771DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P13866SLC5A1
T35734DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P34913EPHX2
T35734DI0190Hypertension[ICD-11: BA00-BA04]P34913EPHX2
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T70309DI0347Prostate disease[ICD-11: GA91]P18405SRD5A1
T16347DI0009Acute diabete complication[ICD-11: 5A2Y]P18031PTPN1
T16347DI0062Breast cancer[ICD-11: 2C60-2C6Y]P18031PTPN1
T16347DI0308Obesity[ICD-11: 5B80-5B81]P18031PTPN1
T16347DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P18031PTPN1
T49156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P17706PTPN2
T93344DI0118Dermatophytosis[ICD-11: 1F28]Q14534SQLE
T93344DI0385Skin fungal infection disorder[ICD-11: EA60]Q14534SQLE
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T40149DI0184Human immunodeficiency virus disease[ICD-11: 1C60-1C62]P24723PRKCH
T40276DI0123Diffuse large B-cell lymphoma[ICD-11: 2A81]P05771PRKCB
T40276DI0241Lymphoma[ICD-11: 2A80-2A86]P05771PRKCB
T40276DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P05771PRKCB
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T47623DI0020African trypanosomiasis[ICD-11: 1F51]Q9Y251HPSE
T47623DI0310Ocular disease[ICD-11: N.A.]Q9Y251HPSE
T13491DI0030Angina pectoris[ICD-11: BA40]Q99808SLC29A1
T96685DI0133Epidermal dysplasias[ICD-11: EK90]P52789HK2
T22583DI0009Acute diabete complication[ICD-11: 5A2Y]Q9NY91SLC5A4
T22583DI0417Type 2 diabetes mellitus[ICD-11: 5A11]Q9NY91SLC5A4
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T64830DI0108Cushing syndrome[ICD-11: 5A70]P35346SSTR5
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T90782DI0025Alzheimer disease[ICD-11: 8A20]Q15077P2RY6
T59190DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q05513PRKCZ
T47107DI0012Acute myeloid leukaemia[ICD-11: 2A60]P05129PRKCG
T47107DI0248Mastocytosis[ICD-11: 2A21]P05129PRKCG
T15739DI0233Lip/oral cavity/pharynx neoplasm[ICD-11: 2B6E]P04637TP53
T15739DI0323Ovarian dysfunction[ICD-11: 5A80]P04637TP53
T15739DI0413Transplant rejection[ICD-11: NE84]P04637TP53
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025